In vivo emergence of ceftazidime/avibactam resistance in Pseudomonas aeruginosa driven by OXA-1381, a novel W157L Ω-loop variant of OXA-2
Antimicrobial Agents and Chemotherapy · 07.10.2026 · 70 (10)
DOI: 10.1128/aac.00584-26 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 07.10.2026. Verfasst von Gloria Pérez-Rodríguez und 8 weiteren Autor:innen. Beteiligte Einrichtung: Servicio de Microbiología Clínica & Grupo de Investigación en Microbiología, Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hosp…. Hauptthemen laut MEDLINE: Ceftazidime, Pseudomonas aeruginosa, Azabicyclo Compounds, beta-Lactamases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto de Salud Carlos III, Xunta de Galicia, ISCII Juan Rodes Program.
Abstract (Originalsprache)
The emergence of ceftazidime/avibactam resistance in an extended-spectrum β-lactamase (ESBL)-producing Pseudomonas aeruginosa isolate during ceftazidime/avibactam therapy was investigated and the underlying mechanisms elucidated. Two sequential isolates recovered before and after the ceftazidime/avibactam treatment were characterized by antimicrobial susceptibility testing, whole-genome sequencing, and functional and biochemical analyses. The initial isolate was susceptible to ceftazidime/avibactam, whereas the later isolate developed resistance (increase in MIC from 2 to 32 mg/L), accompanied by collateral carbapenem susceptibility. Both isolates co-produced a novel BEL variant (designated BEL-5) and an OXA-2 enzyme, encoded by adjacent genes within a class one integron embedded in a 31,623-bp IncP plasmid. The resistant isolate harbored a previously undescribed OXA-2 variant, designated OXA-1381, carrying a W157L substitution in the Ω-loop. Cloning experiments demonstrated that OXA-1381 is an extended-spectrum variant conferring increased resistance to ceftazidime/avibactam and ceftolozane/tazobactam but decreased resistance to carbapenems. Kinetic analyses revealed a marked increase in the affinity and catalytic efficiency of OXA-1381 against ceftazidime and ceftolozane, while showing reduced hydrolytic activity against meropenem, consistent with the observed phenotypic trade-off. Inhibition assays showed similar susceptibility to avibactam for both enzymes, confirming that resistance was driven by enhanced hydrolysis rather than by impaired inhibition. The findings document the in vivo evolution of ceftazidime/avibactam resistance in an ESBL-producing P. aeruginosa background, mediated by structural modification of a narrow-spectrum OXA-2 enzyme. In addition, they highlight the potential of integron-borne genes encoding “silent” β-lactamases to evolve under antibiotic pressure and compromise the activity of last-line agents.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Servicio de Microbiología Clínica & Grupo de Investigación en Microbiología, Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), SERGAS, Universidade da Co…
- CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.
- Servicio de Microbiología, Servicio de Microbiología and Unidad de Investigación, Hospital Universitario Son Espases, Instituto de Investigación Sanitaria Illes Balears (IdISBa), Palma de Mallorca, Spain.
- Departamento de Fisioterapia, Medicina y Ciencias Biomédicas, Universidade da Coruña, A Coruña, Spain.
ORCID-Profile: Gloria Pérez-Rodríguez, Lucía González-Pinto, Pablo Aja-Macaya, Carlos Molina-Cáceres, Lucía Sánchez-Peña, Tania Blanco-Martín, Antonio Oliver, Germán Bou, Jorge Arca-Suárez
Förderung
- Instituto de Salud Carlos III
- Xunta de Galicia
- ISCII Juan Rodes Program
- Centro de Investigacion Biomedica en Red de Enfermedades Infecciosas
- ISCIII PFIS program
Zitieren
APA
Pérez-Rodríguez, G., González-Pinto, L., Aja-Macaya, P., Molina-Cáceres, C., Sánchez-Peña, L., Blanco-Martín, T., Oliver, A., Bou, G., & Arca-Suárez, J. (2026). In vivo emergence of ceftazidime/avibactam resistance in Pseudomonas aeruginosa driven by OXA-1381, a novel W157L Ω-loop variant of OXA-2. Antimicrobial Agents and Chemotherapy, 70(10). https://doi.org/10.1128/aac.00584-26
Vancouver
Pérez-Rodríguez G, González-Pinto L, Aja-Macaya P, Molina-Cáceres C, Sánchez-Peña L, Blanco-Martín T, et al. In vivo emergence of ceftazidime/avibactam resistance in Pseudomonas aeruginosa driven by OXA-1381, a novel W157L Ω-loop variant of OXA-2. Antimicrobial Agents and Chemotherapy. 2026;70(10). doi:10.1128/aac.00584-26
BibTeX
@article{PrezRodrguez2026,
author = {Pérez-Rodríguez, Gloria and González-Pinto, Lucía and Aja-Macaya, Pablo and Molina-Cáceres, Carlos and Sánchez-Peña, Lucía and Blanco-Martín, Tania and Oliver, Antonio and Bou, Germán and Arca-Suárez, Jorge},
title = {In vivo emergence of ceftazidime/avibactam resistance in Pseudomonas aeruginosa driven by OXA-1381, a novel W157L Ω-loop variant of OXA-2},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2026},
volume = {70},
number = {10},
doi = {10.1128/aac.00584-26}
}
EUVIMED